Full-Service Capabilities Metrics, Inc. offers comprehensive development, analytical testing, and commercial manufacturing services within a single FDA-registered site, enabling clients to streamline their product lifecycle from concept to market without complex site transfers, making it an attractive partner for end-to-end pharmaceutical projects.

Strategic Acquisition by Catalent Following Catalent's acquisition of Metrics for 475 million dollars in August 2022, the company now benefits from increased industry visibility, expanded global reach, and greater resources, positioning it for potential collaboration with clients seeking robust manufacturing solutions backed by a major pharma player.

Recent Facility Expansion The expansion of Metrics' Greenville campus signals capacity growth and enhanced capabilities in formulation development and manufacturing, providing sales opportunities with clients seeking reliable supply chain scaling and advanced technical services in oral dosage forms.

Market Focus and Expertise Specializing in novel oral dosage forms with a focus on end-to-end CDMO services, Metrics attracts companies developing innovative therapies, especially those requiring seamless scale-up and analytical testing, opening avenues to collaborate with emerging biotech and pharmaceutical companies.

Client Satisfaction and Growth With over 95 percent of clients willing to re-engage, Metrics demonstrates strong customer loyalty and service quality, indicating excellent partnership potential for businesses seeking a dependable manufacturing partner with proven industry reputation and scalable solutions.